🟢 Capricor Therapeutics is trading 14.96% up today on deramiocel PDUFA deadline extension

Capricor Therapeutics is trading at $9.53 (+14.96%) after the FDA extended deramiocel’s PDUFA deadline to November 22, 2026, allowing review of new HOPE-3 data and analyses.

• The move follows a 21.91% gain on August 25.
• Oppenheimer upgraded Capricor Therapeutics to Outperform with a $54 price target.
• Broader biotech strength provided additional support, but the FDA update remains the primary catalyst.